MS Views and News – a Patient Advocacy Organization that provides educational information for ALL affected by Multiple Sclerosis

Being Empowered with MS information IS beneficial. We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information.

Visit our archived MS educational program video- recordings. Visit

Visit our website: MS Views and

joomla ecommerce template

Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information



'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, October 1, 2009

A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability.

A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults."

FAMPRIDINE-SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.


No comments: